Business
Todos Medical Receives Approval from Israeli Ministry of Health (AMAR) to Market and Sell its Breast Cancer Screens in Israel
Todos Medical Receives Approval from Israeli Ministry of Health (AMAR) to Market and Sell its Breast Cancer Screens in Israel.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\nREHOVOT, Israel, May 23, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that it has received approval from the Israeli Ministry of Health (AMAR) to market and sell its breast cancer tests TM-B1 and TM-B2.\n “We are happy to achieve this important milestone approval from the Ministry of Health of the State of Israel. This approval, along with our recent signing of a distribution agreement for our cancer screens with Care GB in Israel, enables us to move forward at full strength to commercialize our products,” said Dr. Herman Weiss, CEO of Todos Medical. “We are now actively working to begin sales in Austria, Romania and Israel.” Todos Medical has developed cancer screens utilizing its proprietary Total Biochemical Infrared Analysis (TBIA) technology. Todos’s TM-B1 breast cancer screen to detect the presence of malignancy. The Company’s TM-B2 breast cancer screen is designed for women diagnosed with BI-RADS 3 or 4 to distinguish between benign and malignant tumors. Additionally, we are in the process of developing a colon cancer screen. About Todos Medical Ltd. Todos Medical Ltd. (OTCQB: TOMDF), an Israeli company headquartered in Rehovot, is an in-vitro-diagnostic (“IVD”) company engaged in the development of a series of blood tests for the early detection of a variety of cancers and has initiated the development of blood tests for neurodegenerative disorders, such as Alzheimer's disease, through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS). The company has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system which triggers biochemical changes in peripheral blood mononuclear cells (“PBMC”) and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2 are CE marked in the EU. Breakthrough Diagnostics is dev...